Evidence map›Paper›PMID 24244265›Full record

Trial reportPloS one2013

Inhibition of CD4+CD25+ regulatory T cell function and conversion into Th1-like effectors by a Toll-like receptor-activated dendritic cell vaccine.

Major K Lee, Shuwen Xu, Elizabeth H Fitzpatrick, Anupama Sharma, Holly L Graves, Brian J Czerniecki

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Curcumin up regulates T helper 1 cells in patients with colon cancer.American journal of translational research · 2017
    Article
  8. Review
  9. Review
  10. Optimizing dendritic cell-based approaches for cancer immunotherapy.The Yale journal of biology and medicine · 2014
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Major K LeeHarrison Department of Surgical Research, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Shuwen Xu
Elizabeth H Fitzpatrick
Anupama Sharma
Holly L Graves
Brian J Czerniecki
Hospital of the University of Pennsylvania · US

Funding

A HER-2/neu pulsed DC1 vaccine for patients with DCISR01CA096997 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CZERNIECKI, BRIAN JOSEPH · 2003 to 2012
$3.6M
NCI NIH HHS R01 CA096997NCI NIH HHS R01-CA096997-02
6 · The paper itself

Abstract

Despite the success of vaccines against some microbial pathogens, their utility in the prevention and treatment of cancer has thus far been limited. We have previously demonstrated that vaccination with dendritic cells activated with the TLR-4 ligand LPS and IFN-γ promotes an antigen-specific anti-tumor response that prevents tumor recurrence. To evaluate this mechanistically, we here studied the effects of this TLR-activated DC on regulatory T cell activity. Dendritic cells activated with LPS and IFN- γ negated the effects of regulatory T cells on responder cell proliferation. Restoration of responder cell proliferation was noted when TLR-activated dendritic cells were separated from both regulators and responders by a semi-permeable membrane. The effect is therefore mediated by a soluble factor but was independent of both IL-6 and IL-12. Furthermore, the soluble mediator appeared to act at least in part on the regulators themselves rather than responder cells exclusively. Because recent studies have demonstrated conversion of T regulatory cells into IL-17-producing effectors, we further questioned whether the TLR-activated dendritic cell would induce cytokine production and effector function in our system. We found that regulators produced a substantial amount of IFN- γ in the presence of TLR-activated dendritic cells but not immature dendritic cells. IFN-γ production was associated with upregulation of the Th1 transcriptional regulator T-bet, and a significant fraction of IFN-γ-producing regulators coexpressed T-bet and FoxP3. While the effects of the LPS-activated dendritic cell on responder cell proliferation were IL-12 independent, upregulation of T-bet was inhibited by a neutralizing anti-IL-12 antibody. Collectively, these and prior data suggest that varying innate immune signals may direct the phenotype of the immune response in part by inhibiting suppressor T cells and promoting differentiation of these regulators into particular subsets of effectors.

Indexed as

Cancer VaccinesCytokinesDendritic CellsFemaleForkhead Transcription FactorsHumansLipopolysaccharidesMaleT-bet Transcription FactorT-Box Domain ProteinsTh1 CellsT-Lymphocytes, RegulatoryCancer VaccinesCytokinesForkhead Transcription FactorsFOXP3 protein, humanLipopolysaccharidesT-bet Transcription FactorT-Box Domain Proteins

Identifiers

PMID24244265
PMCPMC3823870
OpenAlexW1979580811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.